BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
BioXcel Therapeutics Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation…
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
BioXcel Therapeutics sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based…
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2…
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
BioXcel Therapeutics Company to host conference call at 8 a.m. ET, August 27, 2025 NEW HAVEN, Conn., Aug.…
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Data from more than 2,600 agitation episodes collected Topline data readout is on track for August        …
Is the latest trendy diet actually healthy? Dietitians talk ‘fibermaxxing’
Chia seeds, legumes and Greek yogurt are taking over TikTok as part of a new trend called “fibermaxxing.”…